Trial Outcomes & Findings for A Study to Learn How Well a Higher Amount of Aflibercept Given as an Injection Into the Eye Works and How Safe it is in People With Reduced Vision Due to Swelling in the Macula, Central Part of the Retina Caused by a Blocked Vein in the Retina (Macula Edema Secondary to Retinal Vein Occlusion) (NCT NCT05850520)
NCT ID: NCT05850520
Last Updated: 2026-06-17
Results Overview
BCVA: Best-Corrected Visual Acuity; ETDRS: Early Treatment Diabetic Retinopathy Study; ETDRS letter score (ranging from 0 to 100 letters). A higher letter score means a better outcome (better visual acuity)
Recruitment status
COMPLETED
Study phase
PHASE3
Target enrollment
892 participants
Primary outcome timeframe
At Week 36
Results posted on
2026-06-17
Participant Flow
The study was conducted at 237 centers in Europe, America, Japan, and Asia-Pacific between 15-May-2023 (first participant first visit) and 27-May-2025 (last participant last visit) (Week 64).
In total 1282 participants were screened, of whom 388 participants were screen failures. Overall, 892 participants were randomized and treated. Of these,795 participants completed the treatment phase through Week 64.
Participant milestones
| Measure |
Aflibercept 2q4
Participants received aflibercept 2 mg administered every 4 weeks.
|
Aflibercept 8q8/3
Participants received aflibercept 8 mg administered every 8 weeks, after 3 initial injections at 4-week intervals.
|
Aflibercept 8q8/5
Participants received aflibercept 8 mg administered every 8 weeks, after 5 initial injections at 4-week intervals.
|
|---|---|---|---|
|
Overall Study
STARTED
|
301
|
293
|
298
|
|
Overall Study
COMPLETED
|
270
|
268
|
256
|
|
Overall Study
NOT COMPLETED
|
31
|
25
|
42
|
Reasons for withdrawal
| Measure |
Aflibercept 2q4
Participants received aflibercept 2 mg administered every 4 weeks.
|
Aflibercept 8q8/3
Participants received aflibercept 8 mg administered every 8 weeks, after 3 initial injections at 4-week intervals.
|
Aflibercept 8q8/5
Participants received aflibercept 8 mg administered every 8 weeks, after 5 initial injections at 4-week intervals.
|
|---|---|---|---|
|
Overall Study
Withdrawal by Subject
|
18
|
13
|
28
|
|
Overall Study
Lost to Follow-up
|
5
|
4
|
5
|
|
Overall Study
Death
|
3
|
2
|
5
|
|
Overall Study
Adverse Event
|
3
|
2
|
3
|
|
Overall Study
Physician Decision
|
0
|
2
|
0
|
|
Overall Study
Protocol deviation
|
0
|
0
|
1
|
|
Overall Study
Logistical problem
|
2
|
2
|
0
|
Baseline Characteristics
A Study to Learn How Well a Higher Amount of Aflibercept Given as an Injection Into the Eye Works and How Safe it is in People With Reduced Vision Due to Swelling in the Macula, Central Part of the Retina Caused by a Blocked Vein in the Retina (Macula Edema Secondary to Retinal Vein Occlusion)
Baseline characteristics by cohort
| Measure |
Aflibercept 8q8/5
n=298 Participants
Participants received aflibercept 8 mg administered every 8 weeks, after 5 initial injections at 4-week intervals.
|
Total
n=892 Participants
Total of all reporting groups
|
Aflibercept 2q4
n=301 Participants
Participants received aflibercept 2 mg administered every 4 weeks.
|
Aflibercept 8q8/3
n=293 Participants
Participants received aflibercept 8 mg administered every 8 weeks, after 3 initial injections at 4-week intervals.
|
|---|---|---|---|---|
|
Age, Continuous
|
65.8 Years
STANDARD_DEVIATION 11.5 • n=267 Participants
|
65.9 Years
STANDARD_DEVIATION 11.6 • n=265 Participants
|
65.9 Years
STANDARD_DEVIATION 11.7 • n=9 Participants
|
65.8 Years
STANDARD_DEVIATION 11.5 • n=27 Participants
|
|
Sex: Female, Male
Female
|
146 Participants
n=267 Participants
|
426 Participants
n=265 Participants
|
144 Participants
n=9 Participants
|
136 Participants
n=27 Participants
|
|
Sex: Female, Male
Male
|
152 Participants
n=267 Participants
|
466 Participants
n=265 Participants
|
157 Participants
n=9 Participants
|
157 Participants
n=27 Participants
|
|
Ethnicity (NIH/OMB)
Hispanic or Latino
|
14 Participants
n=267 Participants
|
61 Participants
n=265 Participants
|
22 Participants
n=9 Participants
|
25 Participants
n=27 Participants
|
|
Ethnicity (NIH/OMB)
Not Hispanic or Latino
|
273 Participants
n=267 Participants
|
794 Participants
n=265 Participants
|
267 Participants
n=9 Participants
|
254 Participants
n=27 Participants
|
|
Ethnicity (NIH/OMB)
Unknown or Not Reported
|
11 Participants
n=267 Participants
|
37 Participants
n=265 Participants
|
12 Participants
n=9 Participants
|
14 Participants
n=27 Participants
|
|
Race/Ethnicity, Customized
American Indian or Alaskan Native
|
2 Participants
n=267 Participants
|
2 Participants
n=265 Participants
|
0 Participants
n=9 Participants
|
0 Participants
n=27 Participants
|
|
Race/Ethnicity, Customized
Asian
|
97 Participants
n=267 Participants
|
289 Participants
n=265 Participants
|
101 Participants
n=9 Participants
|
91 Participants
n=27 Participants
|
|
Race/Ethnicity, Customized
Black or African American
|
9 Participants
n=267 Participants
|
24 Participants
n=265 Participants
|
8 Participants
n=9 Participants
|
7 Participants
n=27 Participants
|
|
Race/Ethnicity, Customized
Multiple
|
1 Participants
n=267 Participants
|
2 Participants
n=265 Participants
|
1 Participants
n=9 Participants
|
0 Participants
n=27 Participants
|
|
Race/Ethnicity, Customized
Native Hawaiian or other Pacific Islander
|
1 Participants
n=267 Participants
|
1 Participants
n=265 Participants
|
0 Participants
n=9 Participants
|
0 Participants
n=27 Participants
|
|
Race/Ethnicity, Customized
Not reported
|
11 Participants
n=267 Participants
|
46 Participants
n=265 Participants
|
13 Participants
n=9 Participants
|
22 Participants
n=27 Participants
|
|
Race/Ethnicity, Customized
White
|
177 Participants
n=267 Participants
|
528 Participants
n=265 Participants
|
178 Participants
n=9 Participants
|
173 Participants
n=27 Participants
|
PRIMARY outcome
Timeframe: At Week 36Population: Full analysis set (FAS): All participants randomly assigned to study intervention who were exposed to study intervention (active or sham injection) at least once.
BCVA: Best-Corrected Visual Acuity; ETDRS: Early Treatment Diabetic Retinopathy Study; ETDRS letter score (ranging from 0 to 100 letters). A higher letter score means a better outcome (better visual acuity)
Outcome measures
| Measure |
Aflibercept 8q8/5
n=293 Participants
Participants received aflibercept 8 mg administered every 8 weeks, after 5 initial injections at 4-week intervals.
|
Aflibercept 2q4
n=301 Participants
Participants received aflibercept 2 mg administered every 4 weeks.
|
Aflibercept 8q8/5
n=298 Participants
Participants received aflibercept 8 mg administered every 8 weeks, after 5 initial injections at 4-week intervals.
|
All Aflibercept HD
Pooled aflibercept 8 mg administered every 8 weeks, after 3 or 5 initial injections at 4-week intervals.
|
|---|---|---|---|---|
|
Change From Baseline in BCVA Measured by the ETDRS Letter Score at Week 36
|
17.4 Letters
Standard Error 0.7
|
17.5 Letters
Standard Error 0.7
|
18.3 Letters
Standard Error 0.6
|
—
|
SECONDARY outcome
Timeframe: From baseline to Week 64Population: Full analysis set (FAS): All participants randomly assigned to study intervention who were exposed to study intervention (active or sham injection) at least once.
Active injections refer to the number of injections that were actually administered, as opposed to the number of planned injections.
Outcome measures
| Measure |
Aflibercept 8q8/5
n=293 Participants
Participants received aflibercept 8 mg administered every 8 weeks, after 5 initial injections at 4-week intervals.
|
Aflibercept 2q4
n=301 Participants
Participants received aflibercept 2 mg administered every 4 weeks.
|
Aflibercept 8q8/5
n=298 Participants
Participants received aflibercept 8 mg administered every 8 weeks, after 5 initial injections at 4-week intervals.
|
All Aflibercept HD
Pooled aflibercept 8 mg administered every 8 weeks, after 3 or 5 initial injections at 4-week intervals.
|
|---|---|---|---|---|
|
Number of Active Injections From Baseline to Week 64
|
8.5 Number of active injections
Standard Error 0.1
|
11.7 Number of active injections
Standard Error 0.1
|
9.5 Number of active injections
Standard Error 0.1
|
—
|
SECONDARY outcome
Timeframe: From baseline to Week 36Population: Full analysis set (FAS): All participants randomly assigned to study intervention who were exposed to study intervention (active or sham injection) at least once.
Active injections refer to the number of injections that were actually administered, as opposed to the number of planned injections.
Outcome measures
| Measure |
Aflibercept 8q8/5
n=293 Participants
Participants received aflibercept 8 mg administered every 8 weeks, after 5 initial injections at 4-week intervals.
|
Aflibercept 2q4
n=301 Participants
Participants received aflibercept 2 mg administered every 4 weeks.
|
Aflibercept 8q8/5
n=298 Participants
Participants received aflibercept 8 mg administered every 8 weeks, after 5 initial injections at 4-week intervals.
|
All Aflibercept HD
Pooled aflibercept 8 mg administered every 8 weeks, after 3 or 5 initial injections at 4-week intervals.
|
|---|---|---|---|---|
|
Number of Active Injections From Baseline to Week 36
|
6.1 Number of active injections
Standard Error 0.0
|
8.8 Number of active injections
Standard Error 0.0
|
6.9 Number of active injections
Standard Error 0.0
|
—
|
SECONDARY outcome
Timeframe: At Week 44Population: Full analysis set (FAS): All participants randomly assigned to study intervention who were exposed to study intervention (active or sham injection) at least once.
BCVA: Best-Corrected Visual Acuity; ETDRS: Early Treatment Diabetic Retinopathy Study; ETDRS letter score (ranging from 0 to 100 letters). A higher letter score means a better outcome (better visual acuity). \*This endpoint was only measured for the 8q8/5 and 2q4 groups
Outcome measures
| Measure |
Aflibercept 8q8/5
n=298 Participants
Participants received aflibercept 8 mg administered every 8 weeks, after 5 initial injections at 4-week intervals.
|
Aflibercept 2q4
n=301 Participants
Participants received aflibercept 2 mg administered every 4 weeks.
|
Aflibercept 8q8/5
Participants received aflibercept 8 mg administered every 8 weeks, after 5 initial injections at 4-week intervals.
|
All Aflibercept HD
Pooled aflibercept 8 mg administered every 8 weeks, after 3 or 5 initial injections at 4-week intervals.
|
|---|---|---|---|---|
|
Change From Baseline in BCVA Measured by the ETDRS Letter Score at Week 44*
|
18.8 Letters
Standard Error 0.7
|
17.8 Letters
Standard Error 0.7
|
—
|
—
|
SECONDARY outcome
Timeframe: At Week 64Population: Full analysis set (FAS): All participants randomly assigned to study intervention who were exposed to study intervention (active or sham injection) at least once.
BCVA: Best-Corrected Visual Acuity; ETDRS: Early Treatment Diabetic Retinopathy Study; ETDRS letter score (ranging from 0 to 100 letters). A higher letter score means a better outcome (better visual acuity)
Outcome measures
| Measure |
Aflibercept 8q8/5
n=293 Participants
Participants received aflibercept 8 mg administered every 8 weeks, after 5 initial injections at 4-week intervals.
|
Aflibercept 2q4
n=301 Participants
Participants received aflibercept 2 mg administered every 4 weeks.
|
Aflibercept 8q8/5
n=298 Participants
Participants received aflibercept 8 mg administered every 8 weeks, after 5 initial injections at 4-week intervals.
|
All Aflibercept HD
Pooled aflibercept 8 mg administered every 8 weeks, after 3 or 5 initial injections at 4-week intervals.
|
|---|---|---|---|---|
|
Change From Baseline in BCVA Measured by the ETDRS Letter Score at Week 64
|
17.8 Letters
Standard Error 0.7
|
17.3 Letters
Standard Error 0.8
|
18.1 Letters
Standard Error 0.8
|
—
|
SECONDARY outcome
Timeframe: From baseline at Weeks 36 and 64Population: Full analysis set (FAS): All participants randomly assigned and exposed to study intervention (active or sham injection) at least once. The Overall Number of Participants Analyzed differs from the Overall Number of Baseline Participants because only observed cases were used, excluding data after an intercurrent event (ICE) (e.g., stopping intervention or using prohibited medication before Week 36). Missing cases were not included.
Outcome measures
| Measure |
Aflibercept 8q8/5
n=293 Participants
Participants received aflibercept 8 mg administered every 8 weeks, after 5 initial injections at 4-week intervals.
|
Aflibercept 2q4
n=301 Participants
Participants received aflibercept 2 mg administered every 4 weeks.
|
Aflibercept 8q8/5
n=298 Participants
Participants received aflibercept 8 mg administered every 8 weeks, after 5 initial injections at 4-week intervals.
|
All Aflibercept HD
Pooled aflibercept 8 mg administered every 8 weeks, after 3 or 5 initial injections at 4-week intervals.
|
|---|---|---|---|---|
|
Participants Gaining at Least 15 Letters in BCVA From Baseline at Weeks 36 and 64
Number of participants who gained at least 15 letters in BCVA at Week 64
|
156 Participants
|
154 Participants
|
161 Participants
|
—
|
|
Participants Gaining at Least 15 Letters in BCVA From Baseline at Weeks 36 and 64
Number of participants who gained at least 15 letters in BCVA at Week 36
|
153 Participants
|
158 Participants
|
161 Participants
|
—
|
SECONDARY outcome
Timeframe: At Weeks 36 and 64Population: Full analysis set (FAS): All participants randomly assigned and exposed to study intervention (active or sham injection) at least once. The Overall Number of Participants Analyzed differs from the Overall Number of Baseline Participants because only observed cases were used, excluding data after an intercurrent event (ICE) (e.g., stopping intervention or using prohibited medication before Week 36). Missing cases were not included.
ETDRS letter score (ranging from 0 to 100 letters). A higher letter score means a better outcome (better visual acuity)
Outcome measures
| Measure |
Aflibercept 8q8/5
n=293 Participants
Participants received aflibercept 8 mg administered every 8 weeks, after 5 initial injections at 4-week intervals.
|
Aflibercept 2q4
n=301 Participants
Participants received aflibercept 2 mg administered every 4 weeks.
|
Aflibercept 8q8/5
n=298 Participants
Participants received aflibercept 8 mg administered every 8 weeks, after 5 initial injections at 4-week intervals.
|
All Aflibercept HD
Pooled aflibercept 8 mg administered every 8 weeks, after 3 or 5 initial injections at 4-week intervals.
|
|---|---|---|---|---|
|
Participants Achieving an ETDRS Letter Score of at Least 69 (Approximate 20/40 Snellen Equivalent) at Weeks 36 and 64
Participants who achieved letter score of at least 69 letters at Week 36
|
189 Participants
|
179 Participants
|
189 Participants
|
—
|
|
Participants Achieving an ETDRS Letter Score of at Least 69 (Approximate 20/40 Snellen Equivalent) at Weeks 36 and 64
Participants who achieved letter score of at least 69 letters at Week 64
|
178 Participants
|
179 Participants
|
181 Participants
|
—
|
SECONDARY outcome
Timeframe: At Weeks 36 and 64Population: Full analysis set (FAS): All participants randomly assigned and exposed to study intervention (active or sham injection) at least once. The Overall Number of Participants Analyzed differs from the Overall Number of Baseline Participants because only observed cases were used, excluding data after an intercurrent event (ICE) (e.g., stopping intervention or using prohibited medication before Week 36). Missing cases were not included.
Number of participants with no retinal fluid (no IRF and no SRF) in the central subfield at Weeks 36 and 64
Outcome measures
| Measure |
Aflibercept 8q8/5
n=293 Participants
Participants received aflibercept 8 mg administered every 8 weeks, after 5 initial injections at 4-week intervals.
|
Aflibercept 2q4
n=301 Participants
Participants received aflibercept 2 mg administered every 4 weeks.
|
Aflibercept 8q8/5
n=298 Participants
Participants received aflibercept 8 mg administered every 8 weeks, after 5 initial injections at 4-week intervals.
|
All Aflibercept HD
Pooled aflibercept 8 mg administered every 8 weeks, after 3 or 5 initial injections at 4-week intervals.
|
|---|---|---|---|---|
|
Participants Having no Intraretinal Fluid (IRF) and no Sub-retinal Fluid (SRF) in the Center Subfield at Weeks 36 and 64
Participants with no IRF and no SRF in central subfield at Week 36
|
211 Participants
|
221 Participants
|
202 Participants
|
—
|
|
Participants Having no Intraretinal Fluid (IRF) and no Sub-retinal Fluid (SRF) in the Center Subfield at Weeks 36 and 64
Participants with no IRF and no SRF in central subfield at Week 64
|
193 Participants
|
167 Participants
|
171 Participants
|
—
|
SECONDARY outcome
Timeframe: From baseline to Week 36Population: Full analysis set (FAS): All participants randomly assigned to study intervention who were exposed to study intervention (active or sham injection) at least once.
Outcome measures
| Measure |
Aflibercept 8q8/5
n=293 Participants
Participants received aflibercept 8 mg administered every 8 weeks, after 5 initial injections at 4-week intervals.
|
Aflibercept 2q4
n=301 Participants
Participants received aflibercept 2 mg administered every 4 weeks.
|
Aflibercept 8q8/5
n=298 Participants
Participants received aflibercept 8 mg administered every 8 weeks, after 5 initial injections at 4-week intervals.
|
All Aflibercept HD
Pooled aflibercept 8 mg administered every 8 weeks, after 3 or 5 initial injections at 4-week intervals.
|
|---|---|---|---|---|
|
Change From Baseline in Central Sub-field Thickness (CST) at Week 36
|
-370.9 μm
Standard Error 3.1
|
-370.8 μm
Standard Error 3.9
|
-369.5 μm
Standard Error 2.3
|
—
|
SECONDARY outcome
Timeframe: From baseline to Week 64Population: Full analysis set (FAS): All participants randomly assigned to study intervention who were exposed to study intervention (active or sham injection) at least once.
Outcome measures
| Measure |
Aflibercept 8q8/5
n=293 Participants
Participants received aflibercept 8 mg administered every 8 weeks, after 5 initial injections at 4-week intervals.
|
Aflibercept 2q4
n=301 Participants
Participants received aflibercept 2 mg administered every 4 weeks.
|
Aflibercept 8q8/5
n=298 Participants
Participants received aflibercept 8 mg administered every 8 weeks, after 5 initial injections at 4-week intervals.
|
All Aflibercept HD
Pooled aflibercept 8 mg administered every 8 weeks, after 3 or 5 initial injections at 4-week intervals.
|
|---|---|---|---|---|
|
Change From Baseline in Central Sub-field Thickness (CST) at Week 64
|
-361.1 μm
Standard Error 4.3
|
-353.7 μm
Standard Error 5.2
|
-353.3 μm
Standard Error 4.1
|
—
|
SECONDARY outcome
Timeframe: From baseline to Week 36Population: Full analysis set (FAS): All participants randomly assigned to study intervention who were exposed to study intervention (active or sham injection) at least once.
NEI-VFQ-25: National Eye Institute Visual Functioning Questionnaire-25; The NEI VFQ-25 total score ranges from 0 to 100. A higher score means a better outcome (better patient-reported visual function).
Outcome measures
| Measure |
Aflibercept 8q8/5
n=293 Participants
Participants received aflibercept 8 mg administered every 8 weeks, after 5 initial injections at 4-week intervals.
|
Aflibercept 2q4
n=301 Participants
Participants received aflibercept 2 mg administered every 4 weeks.
|
Aflibercept 8q8/5
n=298 Participants
Participants received aflibercept 8 mg administered every 8 weeks, after 5 initial injections at 4-week intervals.
|
All Aflibercept HD
Pooled aflibercept 8 mg administered every 8 weeks, after 3 or 5 initial injections at 4-week intervals.
|
|---|---|---|---|---|
|
Change From Baseline in NEI VFQ 25 Total Score at Week 36
|
5.91 Scores on a scale
Standard Error 0.61
|
6.27 Scores on a scale
Standard Error 0.67
|
6.92 Scores on a scale
Standard Error 0.63
|
—
|
SECONDARY outcome
Timeframe: From baseline at Week 64Population: Full analysis set (FAS): All participants randomly assigned to study intervention who were exposed to study intervention (active or sham injection) at least once.
NEI-VFQ-25: National Eye Institute Visual Functioning Questionnaire-25; The NEI VFQ-25 total score ranges from 0 to 100. A higher score means a better outcome (better patient-reported visual function).
Outcome measures
| Measure |
Aflibercept 8q8/5
n=293 Participants
Participants received aflibercept 8 mg administered every 8 weeks, after 5 initial injections at 4-week intervals.
|
Aflibercept 2q4
n=301 Participants
Participants received aflibercept 2 mg administered every 4 weeks.
|
Aflibercept 8q8/5
n=298 Participants
Participants received aflibercept 8 mg administered every 8 weeks, after 5 initial injections at 4-week intervals.
|
All Aflibercept HD
Pooled aflibercept 8 mg administered every 8 weeks, after 3 or 5 initial injections at 4-week intervals.
|
|---|---|---|---|---|
|
Change From Baseline in NEI VFQ 25 Total Score at Week 64
|
6.10 Scores on a scale
Standard Error 0.66
|
7.21 Scores on a scale
Standard Error 0.60
|
6.67 Scores on a scale
Standard Error 0.63
|
—
|
SECONDARY outcome
Timeframe: Through Week 36Population: SAF: All participants randomly assigned to study intervention who were exposed to study intervention (active or sham injection) at least once. Analysis of the SAF was performed according to the treatment the participant actually received (as treated). The Overall Number of Participants Analyzed is not consistent with numbers provided in the Overall Number of Baseline Participants because only participants considered as completers for Week 36 were included in the analysis.
Number of participants in the aflibercept 8q8/3 and the aflibercept 8q8/5 groups who were able to maintain every 8 weeks (Q8) dosing through Week 36. Only participants who did not discontinue study intervention prior to Week 36, and were therefore considered "completers" for Week 36, were included in the analysis of this endpoint.
Outcome measures
| Measure |
Aflibercept 8q8/5
n=273 Participants
Participants received aflibercept 8 mg administered every 8 weeks, after 5 initial injections at 4-week intervals.
|
Aflibercept 2q4
n=278 Participants
Participants received aflibercept 2 mg administered every 4 weeks.
|
Aflibercept 8q8/5
n=551 Participants
Participants received aflibercept 8 mg administered every 8 weeks, after 5 initial injections at 4-week intervals.
|
All Aflibercept HD
Pooled aflibercept 8 mg administered every 8 weeks, after 3 or 5 initial injections at 4-week intervals.
|
|---|---|---|---|---|
|
Participants Dosed Only Q8 Through Week 36 in the 8 mg Q8 Group
|
255 Participants
|
246 Participants
|
501 Participants
|
—
|
SECONDARY outcome
Timeframe: At Week 64Population: SAF: All participants randomly assigned to study intervention who were exposed to study intervention (active or sham injection) at least once. The Overall Number of Participants Analyzed is not consistent with the SAF population because only participants who were considered as completers for Week 64 were included in this analysis. Due to the study design, only participants in the 8q8/3 group could complete a Q16 dosing interval, while participants in the 2q4 and 8q8/5 groups could not.
The proportion of participants having last completed treatment interval ≥12 or of 16 weeks at Week 64 for Week 64 completers.
Outcome measures
| Measure |
Aflibercept 8q8/5
n=269 Participants
Participants received aflibercept 8 mg administered every 8 weeks, after 5 initial injections at 4-week intervals.
|
Aflibercept 2q4
n=270 Participants
Participants received aflibercept 2 mg administered every 4 weeks.
|
Aflibercept 8q8/5
n=256 Participants
Participants received aflibercept 8 mg administered every 8 weeks, after 5 initial injections at 4-week intervals.
|
All Aflibercept HD
Pooled aflibercept 8 mg administered every 8 weeks, after 3 or 5 initial injections at 4-week intervals.
|
|---|---|---|---|---|
|
Participant Having Last Treatment Interval ≥12 or of 16 Weeks at Week 64
Last completed dosing interval ≥Q12
|
219 Participants
|
183 Participants
|
201 Participants
|
—
|
|
Participant Having Last Treatment Interval ≥12 or of 16 Weeks at Week 64
Last completed dosing interval Q16
|
151 Participants
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: At Week 64Population: SAF: All participants randomly assigned to study intervention who were exposed to study intervention (active or sham injection) at least once. The Overall Number of Participants Analyzed is not consistent with the SAF population because only participants who were considered as completers for Week 64 were included in this analysis. Due to the study design, only participants in the 8q8/3 group could be assigned to a Q20 dosing interval, while participants in the 2q4 and 8q8/5 groups could not.
The proportion of participants having last intended treatment interval ≥12, ≥16 or 20 weeks at Week 64 for Week 64 completers.
Outcome measures
| Measure |
Aflibercept 8q8/5
n=269 Participants
Participants received aflibercept 8 mg administered every 8 weeks, after 5 initial injections at 4-week intervals.
|
Aflibercept 2q4
n=270 Participants
Participants received aflibercept 2 mg administered every 4 weeks.
|
Aflibercept 8q8/5
n=256 Participants
Participants received aflibercept 8 mg administered every 8 weeks, after 5 initial injections at 4-week intervals.
|
All Aflibercept HD
Pooled aflibercept 8 mg administered every 8 weeks, after 3 or 5 initial injections at 4-week intervals.
|
|---|---|---|---|---|
|
Participant Having Next Intended Interval ≥12, ≥16 or of 20 Weeks at Week 64
Last intended dosing interval ≥Q12
|
232 Participants
|
210 Participants
|
219 Participants
|
—
|
|
Participant Having Next Intended Interval ≥12, ≥16 or of 20 Weeks at Week 64
Last intended dosing interval ≥Q16
|
173 Participants
|
135 Participants
|
159 Participants
|
—
|
|
Participant Having Next Intended Interval ≥12, ≥16 or of 20 Weeks at Week 64
Last intended dosing interval Q20
|
109 Participants
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: Through Weeks 36 and 64Population: Safety analysis set (SAF): All participants randomly assigned to study intervention who were exposed to study intervention (active or sham injection) at least once. Analysis of the SAF was performed according to the treatment the participant actually received (as treated).
TEAEs were defined as AEs that occurred in the time frame from first injection (active or sham) to the last injection (active or sham) plus 30 days. Ocular TEAEs in study eye and non-ocular TEAEs are included (ocular TEAEs in fellow eye are excluded)
Outcome measures
| Measure |
Aflibercept 8q8/5
n=293 Participants
Participants received aflibercept 8 mg administered every 8 weeks, after 5 initial injections at 4-week intervals.
|
Aflibercept 2q4
n=301 Participants
Participants received aflibercept 2 mg administered every 4 weeks.
|
Aflibercept 8q8/5
n=298 Participants
Participants received aflibercept 8 mg administered every 8 weeks, after 5 initial injections at 4-week intervals.
|
All Aflibercept HD
n=591 Participants
Pooled aflibercept 8 mg administered every 8 weeks, after 3 or 5 initial injections at 4-week intervals.
|
|---|---|---|---|---|
|
Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) Through Weeks 36 and 64
Number of participants with TEAEs at Week 36
|
184 Participants
|
188 Participants
|
176 Participants
|
360 Participants
|
|
Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) Through Weeks 36 and 64
Number of participants with TESAEs at Week 36
|
23 Participants
|
32 Participants
|
26 Participants
|
49 Participants
|
|
Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) Through Weeks 36 and 64
Number of participants with TEAEs at Week 64
|
220 Participants
|
226 Participants
|
211 Participants
|
431 Participants
|
|
Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) Through Weeks 36 and 64
Number of participants with TESAEs at Week 64
|
37 Participants
|
44 Participants
|
38 Participants
|
75 Participants
|
SECONDARY outcome
Timeframe: From baseline through Week 36 and 64Population: Pharmacokinetic analysis set (PKS): All participants randomly assigned to study intervention with at least one non-missing PK result after the first dose of study intervention.
Total aflibercept is the sum of free and adjusted bound aflibercept.
Outcome measures
| Measure |
Aflibercept 8q8/5
n=290 Participants
Participants received aflibercept 8 mg administered every 8 weeks, after 5 initial injections at 4-week intervals.
|
Aflibercept 2q4
n=299 Participants
Participants received aflibercept 2 mg administered every 4 weeks.
|
Aflibercept 8q8/5
n=294 Participants
Participants received aflibercept 8 mg administered every 8 weeks, after 5 initial injections at 4-week intervals.
|
All Aflibercept HD
Pooled aflibercept 8 mg administered every 8 weeks, after 3 or 5 initial injections at 4-week intervals.
|
|---|---|---|---|---|
|
Systemic Exposure to Aflibercept as Assessed by Plasma Concentrations of Free, Adjusted Bound and Total Aflibercept From Baseline Through Weeks 36 and 64
Week 12
|
451.7 ng/mL
Geometric Coefficient of Variation 58.83
|
151.5 ng/mL
Geometric Coefficient of Variation 56.99
|
452.6 ng/mL
Geometric Coefficient of Variation 57.04
|
—
|
|
Systemic Exposure to Aflibercept as Assessed by Plasma Concentrations of Free, Adjusted Bound and Total Aflibercept From Baseline Through Weeks 36 and 64
Week 16
|
470.5 ng/mL
Geometric Coefficient of Variation 58.24
|
241.6 ng/mL
Geometric Coefficient of Variation 48.33
|
728.0 ng/mL
Geometric Coefficient of Variation 43.80
|
—
|
|
Systemic Exposure to Aflibercept as Assessed by Plasma Concentrations of Free, Adjusted Bound and Total Aflibercept From Baseline Through Weeks 36 and 64
Week 24
|
179.1 ng/mL
Geometric Coefficient of Variation 73.00
|
164.1 ng/mL
Geometric Coefficient of Variation 61.42
|
202.5 ng/mL
Geometric Coefficient of Variation 80.94
|
—
|
|
Systemic Exposure to Aflibercept as Assessed by Plasma Concentrations of Free, Adjusted Bound and Total Aflibercept From Baseline Through Weeks 36 and 64
Week 36
|
373.9 ng/mL
Geometric Coefficient of Variation 61.16
|
176.4 ng/mL
Geometric Coefficient of Variation 63.65
|
356.9 ng/mL
Geometric Coefficient of Variation 71.10
|
—
|
|
Systemic Exposure to Aflibercept as Assessed by Plasma Concentrations of Free, Adjusted Bound and Total Aflibercept From Baseline Through Weeks 36 and 64
Week 4
|
281.8 ng/mL
Geometric Coefficient of Variation 52.16
|
91.6 ng/mL
Geometric Coefficient of Variation 55.82
|
270.7 ng/mL
Geometric Coefficient of Variation 63.78
|
—
|
|
Systemic Exposure to Aflibercept as Assessed by Plasma Concentrations of Free, Adjusted Bound and Total Aflibercept From Baseline Through Weeks 36 and 64
Week 64
|
197.5 ng/mL
Geometric Coefficient of Variation 123.33
|
NA ng/mL
Geometric Coefficient of Variation NA
Not calculated (less than 2/3 of values per timepoint are ≥ lower limit of quantification \[LLOQ\] for geometric mean calculation).
|
87.4 ng/mL
Geometric Coefficient of Variation 145.01
|
—
|
Adverse Events
Aflibercept 2q4
Serious events: 44 serious events
Other events: 226 other events
Deaths: 3 deaths
Aflibercept 8q8/3
Serious events: 37 serious events
Other events: 220 other events
Deaths: 2 deaths
Aflibercept 8q8/5
Serious events: 38 serious events
Other events: 211 other events
Deaths: 5 deaths
All Aflibercept 8mg
Serious events: 75 serious events
Other events: 431 other events
Deaths: 7 deaths
Serious adverse events
| Measure |
Aflibercept 2q4
n=301 participants at risk
Aflibercept 2mg administered every 4 weeks.
|
Aflibercept 8q8/3
n=293 participants at risk
Aflibercept 8mg administered every 8 weeks, after 3 initial injections at 4-week intervals.
|
Aflibercept 8q8/5
n=298 participants at risk
Aflibercept 8mg administered every 8 weeks, after 5 initial injections at 4-week intervals.
|
All Aflibercept 8mg
n=591 participants at risk
Pooled aflibercept 8mg administered every 8 weeks, after 3 or 5 initial injections at 4-week intervals.
|
|---|---|---|---|---|
|
Blood and lymphatic system disorders
Pancytopenia
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Cardiac disorders
Acute myocardial infarction
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Cardiac disorders
Atrial fibrillation
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
2/591 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Cardiac disorders
Bradycardia
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.68%
2/293 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
2/591 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Cardiac disorders
Coronary artery disease
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
2/591 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Cardiac disorders
Myocardial infarction
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
2/591 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Cardiac disorders
Acute coronary syndrome
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Ear and labyrinth disorders
Vertigo
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Endocrine disorders
Primary hyperaldosteronism
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Cataract
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Retinal artery occlusion
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Retinal detachment
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Retinal vasculitis
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Retinal vein occlusion
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Visual acuity reduced
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Macular hole
|
0.66%
2/301 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Gastrointestinal disorders
Abdominal pain upper
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Gastrointestinal disorders
Hiatus hernia
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Gastrointestinal disorders
Small intestinal obstruction
|
0.33%
1/301 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Gastrointestinal disorders
Lower gastrointestinal haemorrhage
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Gastrointestinal disorders
Femoral hernia incarcerated
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
General disorders and administration site conditions
Incarcerated hernia
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
General disorders and administration site conditions
Oedema
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
General disorders and administration site conditions
General physical health deterioration
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Hepatobiliary disorders
Cholecystitis acute
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Hepatobiliary disorders
Cholecystitis chronic
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Hepatobiliary disorders
Hepatic cyst
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Immune system disorders
Anaphylactic reaction
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Infections and infestations
Bronchitis
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Infections and infestations
Diverticulitis
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.68%
2/293 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.51%
3/591 • Number of events 3 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Infections and infestations
Endophthalmitis
|
1.00%
3/301 • Number of events 3 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Infections and infestations
Gastroenteritis
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Infections and infestations
Herpes zoster
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Infections and infestations
Osteomyelitis
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Infections and infestations
Pneumonia
|
0.66%
2/301 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.68%
2/293 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.51%
3/591 • Number of events 3 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Infections and infestations
Pneumonia parainfluenzae viral
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Infections and infestations
Pneumonia pseudomonal
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Infections and infestations
Sepsis
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.68%
2/293 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.51%
3/591 • Number of events 3 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Infections and infestations
Urinary tract infection
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Infections and infestations
Infectious pleural effusion
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Infections and infestations
COVID-19
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Injury, poisoning and procedural complications
Brain herniation
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Injury, poisoning and procedural complications
Cartilage injury
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Injury, poisoning and procedural complications
Humerus fracture
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Injury, poisoning and procedural complications
Rib fracture
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
2/591 • Number of events 3 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Injury, poisoning and procedural complications
Snake bite
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Injury, poisoning and procedural complications
Subdural haematoma
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Injury, poisoning and procedural complications
Tendon rupture
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Injury, poisoning and procedural complications
Postoperative thoracic procedure complication
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Injury, poisoning and procedural complications
Skin laceration
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Injury, poisoning and procedural complications
Pelvic fracture
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Injury, poisoning and procedural complications
Procedural pain
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Investigations
Blood urine present
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Metabolism and nutrition disorders
Hypoglycaemia
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Metabolism and nutrition disorders
Type 2 diabetes mellitus
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Musculoskeletal and connective tissue disorders
Haemarthrosis
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Musculoskeletal and connective tissue disorders
Osteoarthritis
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Musculoskeletal and connective tissue disorders
Intervertebral disc compression
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Colon cancer
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Oesophageal carcinoma
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Prostate cancer metastatic
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Prostate cancer stage II
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Rectal cancer
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Squamous cell carcinoma of lung
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
T-cell lymphoma
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lung neoplasm malignant
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastatic neoplasm
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Nervous system disorders
Cerebellar infarction
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Nervous system disorders
Cerebral infarction
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Nervous system disorders
Cerebrovascular accident
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Nervous system disorders
Epilepsy
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Nervous system disorders
Haemorrhage intracranial
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Nervous system disorders
Sciatica
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Nervous system disorders
Lacunar infarction
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Nervous system disorders
Cerebellar stroke
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Nervous system disorders
Atypical migraine
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Psychiatric disorders
Anxiety
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Psychiatric disorders
Mental status changes
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Renal and urinary disorders
Calculus bladder
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Renal and urinary disorders
Nephrolithiasis
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Renal and urinary disorders
Diabetic nephropathy
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Renal and urinary disorders
Urinary tract discomfort
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Reproductive system and breast disorders
Benign prostatic hyperplasia
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Reproductive system and breast disorders
Uterine haemorrhage
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Reproductive system and breast disorders
Pelvic organ prolapse
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Respiratory, thoracic and mediastinal disorders
Chronic obstructive pulmonary disease
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Respiratory, thoracic and mediastinal disorders
Epistaxis
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Respiratory, thoracic and mediastinal disorders
Respiratory failure
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Surgical and medical procedures
Medical induction of coma
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Vascular disorders
Giant cell arteritis
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Vascular disorders
Peripheral artery occlusion
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Vascular disorders
Hypertensive emergency
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Blood and lymphatic system disorders
Iron deficiency anaemia
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Cardiac disorders
Angina unstable
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Cardiac disorders
Cardiac failure
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Cardiac disorders
Cardiac failure acute
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Cardiac disorders
Myocardial ischaemia
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Cardiac disorders
Prinzmetal angina
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Glaucoma
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Vitritis
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Gastrointestinal disorders
Abdominal distension
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Gastrointestinal disorders
Diverticulum
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Gastrointestinal disorders
Diverticulum intestinal haemorrhagic
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Gastrointestinal disorders
Duodenal stenosis
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
General disorders and administration site conditions
Chest pain
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
General disorders and administration site conditions
Oedema due to renal disease
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Infections and infestations
Appendicitis
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Infections and infestations
Pneumonia aspiration
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Infections and infestations
Tooth infection
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Infections and infestations
Infected dermal cyst
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Injury, poisoning and procedural complications
Fall
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Injury, poisoning and procedural complications
Multiple injuries
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Injury, poisoning and procedural complications
Overdose
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Injury, poisoning and procedural complications
Posterior capsule rupture
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Musculoskeletal and connective tissue disorders
Vertebral foraminal stenosis
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Bladder cancer
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Bladder neoplasm
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Small cell lung cancer
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Nervous system disorders
Haemorrhagic stroke
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Nervous system disorders
Normal pressure hydrocephalus
|
0.33%
1/301 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Nervous system disorders
Seizure
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Nervous system disorders
Spinal claudication
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Nervous system disorders
Syncope
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Nervous system disorders
Transient ischaemic attack
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Psychiatric disorders
Completed suicide
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Renal and urinary disorders
Ureterolithiasis
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
2/591 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Respiratory, thoracic and mediastinal disorders
Asthma
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Respiratory, thoracic and mediastinal disorders
Dyspnoea exertional
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Surgical and medical procedures
Hip arthroplasty
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Vascular disorders
Circulatory collapse
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Vascular disorders
Hypertensive urgency
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
Other adverse events
| Measure |
Aflibercept 2q4
n=301 participants at risk
Aflibercept 2mg administered every 4 weeks.
|
Aflibercept 8q8/3
n=293 participants at risk
Aflibercept 8mg administered every 8 weeks, after 3 initial injections at 4-week intervals.
|
Aflibercept 8q8/5
n=298 participants at risk
Aflibercept 8mg administered every 8 weeks, after 5 initial injections at 4-week intervals.
|
All Aflibercept 8mg
n=591 participants at risk
Pooled aflibercept 8mg administered every 8 weeks, after 3 or 5 initial injections at 4-week intervals.
|
|---|---|---|---|---|
|
Blood and lymphatic system disorders
Anaemia
|
0.66%
2/301 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.68%
2/293 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
1.0%
3/298 • Number of events 3 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.85%
5/591 • Number of events 5 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Blood and lymphatic system disorders
Iron deficiency anaemia
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Blood and lymphatic system disorders
Lymphocytosis
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Blood and lymphatic system disorders
Monocytosis
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Blood and lymphatic system disorders
Neutrophilia
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Blood and lymphatic system disorders
Thrombocytopenia
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Blood and lymphatic system disorders
Blood loss anaemia
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Cardiac disorders
Aortic valve incompetence
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Cardiac disorders
Arrhythmia
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Cardiac disorders
Arteriosclerosis coronary artery
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Cardiac disorders
Atrial fibrillation
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
1.0%
3/298 • Number of events 3 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.68%
4/591 • Number of events 4 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Cardiac disorders
Atrial tachycardia
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Cardiac disorders
Atrioventricular block first degree
|
0.66%
2/301 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Cardiac disorders
Bradycardia
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Cardiac disorders
Bundle branch block left
|
0.66%
2/301 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Cardiac disorders
Bundle branch block right
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Cardiac disorders
Coronary artery disease
|
0.66%
2/301 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.67%
2/298 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.51%
3/591 • Number of events 3 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Cardiac disorders
Hypertensive heart disease
|
0.66%
2/301 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Cardiac disorders
Mitral valve incompetence
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Cardiac disorders
Myocardial infarction
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Cardiac disorders
Palpitations
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
2/591 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Cardiac disorders
Sinus bradycardia
|
0.66%
2/301 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
1.0%
3/293 • Number of events 3 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.68%
4/591 • Number of events 4 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Cardiac disorders
Tachycardia
|
0.66%
2/301 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
1.0%
3/298 • Number of events 3 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.51%
3/591 • Number of events 3 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Cardiac disorders
Tricuspid valve incompetence
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Cardiac disorders
Ventricular extrasystoles
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Cardiac disorders
Left ventricular hypertrophy
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.67%
2/298 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
2/591 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Cardiac disorders
Left ventricular enlargement
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Cardiac disorders
Ventricular dyssynchrony
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Congenital, familial and genetic disorders
Thalassaemia
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Congenital, familial and genetic disorders
Factor V Leiden mutation
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Ear and labyrinth disorders
Deafness
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Ear and labyrinth disorders
Ear pain
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Ear and labyrinth disorders
Presbyacusis
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Ear and labyrinth disorders
Tinnitus
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Ear and labyrinth disorders
Vertigo
|
0.66%
2/301 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
1.4%
4/293 • Number of events 4 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
2.0%
6/298 • Number of events 7 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
1.7%
10/591 • Number of events 11 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Ear and labyrinth disorders
Vertigo positional
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Ear and labyrinth disorders
Ear inflammation
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Endocrine disorders
Autoimmune thyroiditis
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Endocrine disorders
Thyroid mass
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Aphakia
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.67%
2/298 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
2/591 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Blepharitis
|
0.66%
2/301 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.68%
2/293 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.67%
2/298 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.68%
4/591 • Number of events 4 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Blepharospasm
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
2/591 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Blindness
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Borderline glaucoma
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.68%
2/293 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.51%
3/591 • Number of events 3 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Cataract
|
5.6%
17/301 • Number of events 17 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
3.8%
11/293 • Number of events 11 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
5.7%
17/298 • Number of events 17 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
4.7%
28/591 • Number of events 28 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Cataract cortical
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.68%
2/293 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
2/591 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Cataract nuclear
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Chalazion
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Ciliary muscle spasm
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Conjunctival haemorrhage
|
2.7%
8/301 • Number of events 10 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
4.8%
14/293 • Number of events 15 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
4.0%
12/298 • Number of events 13 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
4.4%
26/591 • Number of events 28 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Conjunctival irritation
|
0.33%
1/301 • Number of events 4 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Conjunctival oedema
|
0.66%
2/301 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Conjunctivitis allergic
|
1.7%
5/301 • Number of events 6 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
1.4%
4/293 • Number of events 5 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
1.0%
3/298 • Number of events 3 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
1.2%
7/591 • Number of events 8 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Corneal infiltrates
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Corneal scar
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Diabetic retinopathy
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Dry eye
|
3.0%
9/301 • Number of events 9 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
1.4%
4/293 • Number of events 4 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
3.0%
9/298 • Number of events 9 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
2.2%
13/591 • Number of events 13 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Eye inflammation
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Eye irritation
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.68%
2/293 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
2/591 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Eye pain
|
1.00%
3/301 • Number of events 3 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
1.7%
5/293 • Number of events 5 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
1.3%
4/298 • Number of events 6 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
1.5%
9/591 • Number of events 11 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Eye swelling
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Glaucoma
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
1.4%
4/293 • Number of events 4 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.67%
2/298 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
1.0%
6/591 • Number of events 6 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Iritis
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Keratitis
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
2/591 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Lenticular opacities
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.67%
2/298 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
2/591 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Macular degeneration
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Macular oedema
|
2.0%
6/301 • Number of events 7 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
3.4%
10/293 • Number of events 12 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
1.7%
5/298 • Number of events 5 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
2.5%
15/591 • Number of events 17 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Maculopathy
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Ocular hyperaemia
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Ocular hypertension
|
1.7%
5/301 • Number of events 5 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
1.7%
5/293 • Number of events 5 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
1.0%
3/298 • Number of events 3 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
1.4%
8/591 • Number of events 8 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Open angle glaucoma
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.68%
2/293 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
2/591 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Optic atrophy
|
0.66%
2/301 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Optic nerve cupping
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.68%
2/293 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
2/591 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Posterior capsule opacification
|
0.33%
1/301 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.67%
2/298 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.51%
3/591 • Number of events 4 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Presbyopia
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Pterygium
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Punctate keratitis
|
2.3%
7/301 • Number of events 7 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
1.4%
4/293 • Number of events 5 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.67%
2/298 • Number of events 3 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
1.0%
6/591 • Number of events 8 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Retinal artery embolism
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Retinal artery occlusion
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Retinal degeneration
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
2/591 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Retinal exudates
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.68%
2/293 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.67%
2/298 • Number of events 3 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.68%
4/591 • Number of events 5 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Retinal haemorrhage
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
1.0%
3/293 • Number of events 5 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
1.0%
3/298 • Number of events 4 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
1.0%
6/591 • Number of events 9 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Retinal ischaemia
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
2/591 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Retinal oedema
|
0.66%
2/301 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
1.0%
3/293 • Number of events 4 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 3 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.68%
4/591 • Number of events 7 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Retinal pigment epitheliopathy
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Retinal tear
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.67%
2/298 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.51%
3/591 • Number of events 3 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Retinal vascular disorder
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.68%
2/293 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.67%
2/298 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.68%
4/591 • Number of events 4 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Retinal vein occlusion
|
0.66%
2/301 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
1.4%
4/293 • Number of events 4 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
1.3%
4/298 • Number of events 6 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
1.4%
8/591 • Number of events 10 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Swelling of eyelid
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Uveitis
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.67%
2/298 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
2/591 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Vision blurred
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
1.0%
3/293 • Number of events 3 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.68%
4/591 • Number of events 4 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Visual acuity reduced
|
3.7%
11/301 • Number of events 13 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
5.5%
16/293 • Number of events 17 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
2.7%
8/298 • Number of events 10 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
4.1%
24/591 • Number of events 27 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Visual field defect
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.68%
2/293 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
2/591 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Visual impairment
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.68%
2/293 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.51%
3/591 • Number of events 3 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Vitreous detachment
|
1.3%
4/301 • Number of events 4 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
3.1%
9/293 • Number of events 9 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
3.4%
10/298 • Number of events 12 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
3.2%
19/591 • Number of events 21 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Vitreous floaters
|
1.3%
4/301 • Number of events 5 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
2.0%
6/293 • Number of events 6 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
1.0%
3/298 • Number of events 3 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
1.5%
9/591 • Number of events 9 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Vitreous haemorrhage
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
1.0%
3/293 • Number of events 3 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.67%
2/298 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.85%
5/591 • Number of events 5 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Vitreous opacities
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.67%
2/298 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.51%
3/591 • Number of events 3 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Xerophthalmia
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
2/591 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Macular hole
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Foreign body sensation in eyes
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Conjunctival hyperaemia
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Eye pruritus
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
1.0%
3/293 • Number of events 3 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.51%
3/591 • Number of events 3 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Ocular discomfort
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Detachment of retinal pigment epithelium
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Keratic precipitates
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Anterior chamber cell
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Allergic keratitis
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Cystoid macular oedema
|
0.66%
2/301 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
1.0%
3/293 • Number of events 4 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.68%
4/591 • Number of events 6 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Eyelid disorder
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Optic neuropathy
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Corneal disorder
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Anterior chamber disorder
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Retinal drusen
|
1.00%
3/301 • Number of events 3 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Epiretinal membrane
|
2.0%
6/301 • Number of events 6 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
2.0%
6/293 • Number of events 6 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
3.4%
10/298 • Number of events 10 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
2.7%
16/591 • Number of events 16 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Meibomian gland dysfunction
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Macular ischaemia
|
0.33%
1/301 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.68%
2/293 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.51%
3/591 • Number of events 3 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Normal tension glaucoma
|
1.00%
3/301 • Number of events 3 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.68%
2/293 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.51%
3/591 • Number of events 3 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Dysmetropsia
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Narrow anterior chamber angle
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
2/591 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Vitreoretinal traction syndrome
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
1.0%
3/293 • Number of events 6 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.68%
4/591 • Number of events 7 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Dry age-related macular degeneration
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Retinal collateral vessels
|
0.66%
2/301 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Conjunctival suffusion
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
2/591 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Macular thickening
|
2.7%
8/301 • Number of events 11 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
4.1%
12/293 • Number of events 12 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
2.2%
13/591 • Number of events 13 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Gastrointestinal disorders
Abdominal pain
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Gastrointestinal disorders
Abdominal pain upper
|
1.00%
3/301 • Number of events 5 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Gastrointestinal disorders
Chronic gastritis
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
2/591 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Gastrointestinal disorders
Constipation
|
1.00%
3/301 • Number of events 3 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
1.4%
4/293 • Number of events 4 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.85%
5/591 • Number of events 5 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Gastrointestinal disorders
Crohn's disease
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Gastrointestinal disorders
Dental caries
|
1.00%
3/301 • Number of events 3 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
1.3%
4/298 • Number of events 5 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.85%
5/591 • Number of events 6 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Gastrointestinal disorders
Diarrhoea
|
1.3%
4/301 • Number of events 4 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
1.0%
3/293 • Number of events 3 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.68%
4/591 • Number of events 4 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Gastrointestinal disorders
Diverticulum intestinal
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Gastrointestinal disorders
Duodenal ulcer
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Gastrointestinal disorders
Dysphagia
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
2/591 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Gastrointestinal disorders
Food poisoning
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Gastrointestinal disorders
Gastritis
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Gastrointestinal disorders
Gastrooesophageal reflux disease
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.68%
2/293 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.51%
3/591 • Number of events 3 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Gastrointestinal disorders
Gastrointestinal disorder
|
0.66%
2/301 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Gastrointestinal disorders
Glossitis
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Gastrointestinal disorders
Haemorrhoids
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.67%
2/298 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
2/591 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Gastrointestinal disorders
Irritable bowel syndrome
|
0.66%
2/301 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Gastrointestinal disorders
Mouth ulceration
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Gastrointestinal disorders
Nausea
|
2.0%
6/301 • Number of events 8 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
1.4%
4/293 • Number of events 5 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
1.0%
3/298 • Number of events 4 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
1.2%
7/591 • Number of events 9 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Gastrointestinal disorders
Oesophagitis
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Gastrointestinal disorders
Pancreatic disorder
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Gastrointestinal disorders
Periodontal disease
|
0.66%
2/301 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Gastrointestinal disorders
Stomatitis
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Gastrointestinal disorders
Toothache
|
0.66%
2/301 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.67%
2/298 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.51%
3/591 • Number of events 3 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Gastrointestinal disorders
Vomiting
|
2.0%
6/301 • Number of events 7 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
2/591 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Gastrointestinal disorders
Large intestine polyp
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
General disorders and administration site conditions
Application site irritation
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
General disorders and administration site conditions
Asthenia
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
General disorders and administration site conditions
Chest pain
|
0.66%
2/301 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
1.4%
4/293 • Number of events 4 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.85%
5/591 • Number of events 5 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
General disorders and administration site conditions
Chills
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
General disorders and administration site conditions
Cyst
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
General disorders and administration site conditions
Fatigue
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
General disorders and administration site conditions
Gait disturbance
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
General disorders and administration site conditions
Hernia
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
General disorders and administration site conditions
Influenza like illness
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.68%
2/293 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.67%
2/298 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.68%
4/591 • Number of events 4 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
General disorders and administration site conditions
Injection site bruising
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
General disorders and administration site conditions
Injection site irritation
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.68%
2/293 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.67%
2/298 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.68%
4/591 • Number of events 4 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
General disorders and administration site conditions
Injection site pain
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
General disorders and administration site conditions
Malaise
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.68%
2/293 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.51%
3/591 • Number of events 3 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
General disorders and administration site conditions
Mass
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
General disorders and administration site conditions
Oedema
|
1.00%
3/301 • Number of events 3 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
General disorders and administration site conditions
Oedema peripheral
|
1.00%
3/301 • Number of events 3 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
1.4%
4/293 • Number of events 4 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.68%
4/591 • Number of events 4 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
General disorders and administration site conditions
Pain
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.68%
2/293 • Number of events 3 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.51%
3/591 • Number of events 4 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
General disorders and administration site conditions
Pyrexia
|
1.3%
4/301 • Number of events 4 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
1.0%
3/293 • Number of events 6 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.68%
4/591 • Number of events 7 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
General disorders and administration site conditions
Peripheral swelling
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
General disorders and administration site conditions
Sensation of foreign body
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
General disorders and administration site conditions
Application site hypersensitivity
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Hepatobiliary disorders
Biliary colic
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Hepatobiliary disorders
Cholelithiasis
|
0.66%
2/301 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Hepatobiliary disorders
Hepatic cyst
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Hepatobiliary disorders
Hepatic steatosis
|
1.3%
4/301 • Number of events 4 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
1.0%
3/298 • Number of events 3 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.51%
3/591 • Number of events 3 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Hepatobiliary disorders
Metabolic dysfunction-associated liver disease
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Immune system disorders
Drug hypersensitivity
|
0.66%
2/301 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
2/591 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Immune system disorders
Hypersensitivity
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Immune system disorders
Multiple allergies
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Immune system disorders
Seasonal allergy
|
1.00%
3/301 • Number of events 3 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
1.4%
4/293 • Number of events 4 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
1.0%
3/298 • Number of events 3 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
1.2%
7/591 • Number of events 7 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Immune system disorders
Allergy to arthropod sting
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Immune system disorders
Allergy to chemicals
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Infections and infestations
Acute sinusitis
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Infections and infestations
Atypical pneumonia
|
0.66%
2/301 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Infections and infestations
Bronchitis
|
1.3%
4/301 • Number of events 4 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
2.0%
6/293 • Number of events 7 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
2.0%
6/298 • Number of events 6 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
2.0%
12/591 • Number of events 13 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Infections and infestations
Chronic hepatitis C
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Infections and infestations
Chronic sinusitis
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Infections and infestations
Conjunctivitis
|
0.66%
2/301 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
1.0%
3/293 • Number of events 3 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
1.0%
3/298 • Number of events 4 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
1.0%
6/591 • Number of events 7 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Infections and infestations
Conjunctivitis viral
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Infections and infestations
Cystitis
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.67%
2/298 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
2/591 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Infections and infestations
Diverticulitis
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
2/591 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Infections and infestations
Epididymitis
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Infections and infestations
Erysipelas
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Infections and infestations
Fungal infection
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Infections and infestations
Fungal skin infection
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.67%
2/298 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
2/591 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Infections and infestations
Gastroenteritis
|
0.66%
2/301 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Infections and infestations
Gastroenteritis viral
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.67%
2/298 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
2/591 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Infections and infestations
Gingivitis
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Infections and infestations
Herpes simplex
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Infections and infestations
Herpes zoster
|
2.0%
6/301 • Number of events 6 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.68%
2/293 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
1.3%
4/298 • Number of events 4 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
1.0%
6/591 • Number of events 6 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Infections and infestations
Hordeolum
|
0.66%
2/301 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.67%
2/298 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.51%
3/591 • Number of events 3 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Infections and infestations
Influenza
|
4.3%
13/301 • Number of events 13 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
3.8%
11/293 • Number of events 12 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
2.0%
6/298 • Number of events 6 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
2.9%
17/591 • Number of events 18 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Infections and infestations
Localised infection
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Infections and infestations
Lower respiratory tract infection
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Infections and infestations
Nasopharyngitis
|
6.6%
20/301 • Number of events 22 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
8.5%
25/293 • Number of events 31 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
9.1%
27/298 • Number of events 33 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
8.8%
52/591 • Number of events 64 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Infections and infestations
Oral candidiasis
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Infections and infestations
Otitis externa
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
2/591 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Infections and infestations
Periodontitis
|
0.66%
2/301 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
1.0%
3/293 • Number of events 3 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.68%
4/591 • Number of events 4 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Infections and infestations
Pharyngitis
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
1.4%
4/293 • Number of events 4 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.85%
5/591 • Number of events 5 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Infections and infestations
Pneumonia
|
0.66%
2/301 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
1.4%
4/293 • Number of events 4 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
1.3%
4/298 • Number of events 4 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
1.4%
8/591 • Number of events 8 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Infections and infestations
Pulpitis dental
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Infections and infestations
Rhinitis
|
0.66%
2/301 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
2/591 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Infections and infestations
Sinusitis
|
1.7%
5/301 • Number of events 7 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
1.4%
4/293 • Number of events 5 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
1.3%
4/298 • Number of events 4 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
1.4%
8/591 • Number of events 9 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Infections and infestations
Tinea cruris
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Infections and infestations
Tinea pedis
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Infections and infestations
Tonsillitis
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.67%
2/298 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.51%
3/591 • Number of events 3 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Infections and infestations
Tooth abscess
|
0.66%
2/301 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Infections and infestations
Upper respiratory tract infection
|
2.7%
8/301 • Number of events 8 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
2.7%
8/293 • Number of events 9 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
1.0%
3/298 • Number of events 7 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
1.9%
11/591 • Number of events 16 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Infections and infestations
Urinary tract infection
|
4.3%
13/301 • Number of events 13 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
2.7%
8/293 • Number of events 9 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
4.7%
14/298 • Number of events 18 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
3.7%
22/591 • Number of events 27 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Infections and infestations
Vaginal infection
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.67%
2/298 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
2/591 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Infections and infestations
Viral infection
|
0.66%
2/301 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
1.0%
3/298 • Number of events 4 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.68%
4/591 • Number of events 5 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Infections and infestations
Viral upper respiratory tract infection
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Infections and infestations
Wound infection
|
0.66%
2/301 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Infections and infestations
Tooth infection
|
0.66%
2/301 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Infections and infestations
Coronavirus infection
|
1.00%
3/301 • Number of events 3 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Infections and infestations
Escherichia urinary tract infection
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Infections and infestations
Helicobacter infection
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Infections and infestations
Asymptomatic bacteriuria
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Infections and infestations
Enterocolitis infectious
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Infections and infestations
Abdominal abscess
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Infections and infestations
Respiratory syncytial virus infection
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Infections and infestations
Respiratory tract infection
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Infections and infestations
Herpes dermatitis
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Infections and infestations
Viral rhinitis
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Infections and infestations
Oral herpes
|
0.66%
2/301 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.68%
2/293 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.51%
3/591 • Number of events 3 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Infections and infestations
Infected dermal cyst
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Infections and infestations
COVID-19
|
2.7%
8/301 • Number of events 8 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
5.5%
16/293 • Number of events 16 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
4.0%
12/298 • Number of events 12 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
4.7%
28/591 • Number of events 28 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Injury, poisoning and procedural complications
Corneal abrasion
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
1.7%
5/298 • Number of events 5 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
1.0%
6/591 • Number of events 6 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Injury, poisoning and procedural complications
Fall
|
1.00%
3/301 • Number of events 3 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.68%
2/293 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
1.3%
4/298 • Number of events 4 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
1.0%
6/591 • Number of events 6 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Injury, poisoning and procedural complications
Foot fracture
|
0.66%
2/301 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Injury, poisoning and procedural complications
Foreign body in eye
|
0.33%
1/301 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Injury, poisoning and procedural complications
Hand fracture
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Injury, poisoning and procedural complications
Injury corneal
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Injury, poisoning and procedural complications
Tendon injury
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Injury, poisoning and procedural complications
Wrist fracture
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Injury, poisoning and procedural complications
Muscle strain
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Injury, poisoning and procedural complications
Contusion
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
1.0%
3/293 • Number of events 3 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
1.3%
4/298 • Number of events 4 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
1.2%
7/591 • Number of events 7 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Injury, poisoning and procedural complications
Postoperative thoracic procedure complication
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Injury, poisoning and procedural complications
Skin laceration
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.68%
2/293 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.51%
3/591 • Number of events 3 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Injury, poisoning and procedural complications
Joint injury
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.67%
2/298 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
2/591 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Injury, poisoning and procedural complications
Limb injury
|
0.66%
2/301 • Number of events 3 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.68%
2/293 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
2/591 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Injury, poisoning and procedural complications
Upper limb fracture
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Injury, poisoning and procedural complications
Procedural pain
|
1.00%
3/301 • Number of events 3 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Injury, poisoning and procedural complications
Bone contusion
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Injury, poisoning and procedural complications
Post procedural swelling
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Injury, poisoning and procedural complications
Procedural nausea
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Injury, poisoning and procedural complications
Injection related reaction
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Injury, poisoning and procedural complications
Meniscus injury
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Injury, poisoning and procedural complications
Oral contusion
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Injury, poisoning and procedural complications
Intra-ocular injection complication
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
1.7%
5/293 • Number of events 5 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.85%
5/591 • Number of events 5 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Investigations
Alanine aminotransferase increased
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.68%
2/293 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.51%
3/591 • Number of events 3 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Investigations
Aspartate aminotransferase increased
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.68%
2/293 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.67%
2/298 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.68%
4/591 • Number of events 4 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Investigations
Bilirubin conjugated increased
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Investigations
Blood albumin increased
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Investigations
Blood bilirubin increased
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Investigations
Blood cholesterol increased
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.68%
2/293 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.67%
2/298 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.68%
4/591 • Number of events 4 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Investigations
Blood creatine increased
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Investigations
Blood creatine phosphokinase increased
|
1.3%
4/301 • Number of events 4 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
1.4%
4/293 • Number of events 4 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
1.7%
5/298 • Number of events 5 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
1.5%
9/591 • Number of events 9 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Investigations
Blood creatinine decreased
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Investigations
Blood glucose increased
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
1.0%
3/293 • Number of events 3 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.68%
4/591 • Number of events 4 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Investigations
Blood iron decreased
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Investigations
Blood potassium increased
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Investigations
Blood pressure diastolic increased
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.68%
2/293 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.67%
2/298 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.68%
4/591 • Number of events 4 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Investigations
Blood pressure increased
|
1.00%
3/301 • Number of events 3 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
2.0%
6/293 • Number of events 7 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
1.3%
4/298 • Number of events 4 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
1.7%
10/591 • Number of events 11 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Investigations
Blood pressure systolic increased
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Investigations
Blood triglycerides increased
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.68%
2/293 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.51%
3/591 • Number of events 3 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Investigations
Blood urea increased
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
2/591 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Investigations
Blood uric acid increased
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.67%
2/298 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
2/591 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Investigations
Electrocardiogram QT prolonged
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Investigations
Glucose urine
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Investigations
Glycosylated haemoglobin increased
|
0.66%
2/301 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
1.4%
4/293 • Number of events 4 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
1.7%
5/298 • Number of events 5 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
1.5%
9/591 • Number of events 9 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Investigations
Haematocrit decreased
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Investigations
Haematocrit increased
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Investigations
Blood urine present
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.67%
2/298 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.51%
3/591 • Number of events 3 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Investigations
Haemoglobin decreased
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Investigations
Haemoglobin increased
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Investigations
Intraocular pressure decreased
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Investigations
Intraocular pressure increased
|
2.7%
8/301 • Number of events 23 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
6.5%
19/293 • Number of events 29 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
5.4%
16/298 • Number of events 28 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
5.9%
35/591 • Number of events 57 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Investigations
Liver function test abnormal
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Investigations
Low density lipoprotein increased
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Investigations
Mean cell haemoglobin decreased
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Investigations
Mean cell volume abnormal
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Investigations
Monocyte count increased
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Investigations
Neutrophil count increased
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Investigations
Platelet count decreased
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Investigations
Protein total increased
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Investigations
Red blood cell count decreased
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Investigations
Weight decreased
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Investigations
Weight increased
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Investigations
White blood cell count increased
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.68%
2/293 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
2/591 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Investigations
White blood cells urine positive
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
2/591 • Number of events 3 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Investigations
Urinary sediment present
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
2/591 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Investigations
Red blood cells urine
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Investigations
Creatinine urine increased
|
0.66%
2/301 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Investigations
Protein urine present
|
1.3%
4/301 • Number of events 4 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
2/591 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Investigations
Urine protein/creatinine ratio increased
|
1.3%
4/301 • Number of events 4 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.67%
2/298 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.51%
3/591 • Number of events 3 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Investigations
Creatinine urine decreased
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Investigations
Optic nerve cup/disc ratio increased
|
0.66%
2/301 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Investigations
Urine ketone body present
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Investigations
Bacterial test positive
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Investigations
Blood alkaline phosphatase increased
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.67%
2/298 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.51%
3/591 • Number of events 3 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Investigations
Intraocular pressure test abnormal
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Investigations
Urine analysis abnormal
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
2/591 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Investigations
Urobilinogen urine increased
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Investigations
Liver function test increased
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Metabolism and nutrition disorders
Acidosis
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Metabolism and nutrition disorders
Dehydration
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Metabolism and nutrition disorders
Diabetes mellitus
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.68%
2/293 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.67%
2/298 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.68%
4/591 • Number of events 4 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Metabolism and nutrition disorders
Diabetic ketoacidosis
|
0.33%
1/301 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Metabolism and nutrition disorders
Diabetic ketosis
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Metabolism and nutrition disorders
Glucose tolerance impaired
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.68%
2/293 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
2/591 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Metabolism and nutrition disorders
Gout
|
1.00%
3/301 • Number of events 3 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Metabolism and nutrition disorders
Hypercholesterolaemia
|
1.7%
5/301 • Number of events 5 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
1.7%
5/293 • Number of events 5 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
2.7%
8/298 • Number of events 8 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
2.2%
13/591 • Number of events 13 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Metabolism and nutrition disorders
Hyperkalaemia
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Metabolism and nutrition disorders
Hypertriglyceridaemia
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.67%
2/298 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
2/591 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Metabolism and nutrition disorders
Hyperuricaemia
|
1.00%
3/301 • Number of events 3 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Metabolism and nutrition disorders
Hypervolaemia
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Metabolism and nutrition disorders
Hypoglycaemia
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Metabolism and nutrition disorders
Hypokalaemia
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.68%
2/293 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.67%
2/298 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.68%
4/591 • Number of events 4 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Metabolism and nutrition disorders
Hyponatraemia
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
2/591 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Metabolism and nutrition disorders
Obesity
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Metabolism and nutrition disorders
Overweight
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Metabolism and nutrition disorders
Vitamin D deficiency
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
2/591 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Metabolism and nutrition disorders
Metabolic syndrome
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Metabolism and nutrition disorders
Dyslipidaemia
|
0.66%
2/301 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
1.0%
3/298 • Number of events 3 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.51%
3/591 • Number of events 3 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Metabolism and nutrition disorders
Lipid metabolism disorder
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
2/591 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Metabolism and nutrition disorders
Vitamin B complex deficiency
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Metabolism and nutrition disorders
Hyperlipidaemia
|
3.0%
9/301 • Number of events 9 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
1.0%
3/293 • Number of events 3 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
1.0%
3/298 • Number of events 3 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
1.0%
6/591 • Number of events 6 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Metabolism and nutrition disorders
Type 2 diabetes mellitus
|
1.7%
5/301 • Number of events 7 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
1.3%
4/298 • Number of events 4 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.85%
5/591 • Number of events 5 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Musculoskeletal and connective tissue disorders
Arthralgia
|
2.3%
7/301 • Number of events 7 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
2.0%
6/293 • Number of events 6 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
2.0%
6/298 • Number of events 6 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
2.0%
12/591 • Number of events 12 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Musculoskeletal and connective tissue disorders
Arthritis
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
1.4%
4/293 • Number of events 5 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.85%
5/591 • Number of events 6 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Musculoskeletal and connective tissue disorders
Back pain
|
2.3%
7/301 • Number of events 7 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
1.0%
3/293 • Number of events 3 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
1.7%
5/298 • Number of events 5 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
1.4%
8/591 • Number of events 8 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Musculoskeletal and connective tissue disorders
Bursitis
|
1.00%
3/301 • Number of events 3 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Musculoskeletal and connective tissue disorders
Dupuytren's contracture
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Musculoskeletal and connective tissue disorders
Joint effusion
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Musculoskeletal and connective tissue disorders
Joint swelling
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.68%
2/293 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
2/591 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Musculoskeletal and connective tissue disorders
Muscle disorder
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Musculoskeletal and connective tissue disorders
Muscle spasms
|
0.66%
2/301 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Musculoskeletal and connective tissue disorders
Musculoskeletal pain
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Musculoskeletal and connective tissue disorders
Myalgia
|
1.3%
4/301 • Number of events 4 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Musculoskeletal and connective tissue disorders
Myositis
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Musculoskeletal and connective tissue disorders
Osteoarthritis
|
1.7%
5/301 • Number of events 5 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
1.0%
3/298 • Number of events 3 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.68%
4/591 • Number of events 4 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Musculoskeletal and connective tissue disorders
Osteoporosis
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.68%
2/293 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
2/591 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Musculoskeletal and connective tissue disorders
Pain in extremity
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
1.7%
5/293 • Number of events 6 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.67%
2/298 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
1.2%
7/591 • Number of events 8 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Musculoskeletal and connective tissue disorders
Periarthritis
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Musculoskeletal and connective tissue disorders
Plantar fasciitis
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Musculoskeletal and connective tissue disorders
Rheumatoid arthritis
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
1.0%
3/293 • Number of events 3 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.51%
3/591 • Number of events 3 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Musculoskeletal and connective tissue disorders
Rotator cuff syndrome
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Musculoskeletal and connective tissue disorders
Scoliosis
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.68%
2/293 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
2/591 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Musculoskeletal and connective tissue disorders
Spinal osteoarthritis
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
1.4%
4/293 • Number of events 4 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.85%
5/591 • Number of events 5 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Musculoskeletal and connective tissue disorders
Systemic lupus erythematosus
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Musculoskeletal and connective tissue disorders
Tenosynovitis
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Musculoskeletal and connective tissue disorders
Musculoskeletal stiffness
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Musculoskeletal and connective tissue disorders
Foot deformity
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Musculoskeletal and connective tissue disorders
Intervertebral disc degeneration
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Musculoskeletal and connective tissue disorders
Tendon pain
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Musculoskeletal and connective tissue disorders
Rheumatic disorder
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Musculoskeletal and connective tissue disorders
Vertebral lateral recess stenosis
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Basal cell carcinoma
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Benign breast neoplasm
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Leiomyoma
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lipoma
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to lymph nodes
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Seborrhoeic keratosis
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Squamous cell carcinoma of skin
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Uterine leiomyoma
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Cancer fatigue
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Nervous system disorders
Amnesia
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Nervous system disorders
Carotid artery stenosis
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Nervous system disorders
Cerebellar infarction
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Nervous system disorders
Cerebral infarction
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Nervous system disorders
Cerebrovascular disorder
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Nervous system disorders
Dementia
|
1.00%
3/301 • Number of events 3 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Nervous system disorders
Dementia Alzheimer's type
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Nervous system disorders
Diabetic neuropathy
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Nervous system disorders
Dizziness
|
1.7%
5/301 • Number of events 6 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
1.0%
3/293 • Number of events 3 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
1.3%
4/298 • Number of events 4 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
1.2%
7/591 • Number of events 7 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Nervous system disorders
Epilepsy
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Nervous system disorders
Facial paralysis
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Nervous system disorders
Headache
|
2.7%
8/301 • Number of events 18 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
3.4%
10/293 • Number of events 10 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
2.3%
7/298 • Number of events 9 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
2.9%
17/591 • Number of events 19 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Nervous system disorders
Hypoaesthesia
|
0.66%
2/301 • Number of events 3 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Nervous system disorders
Memory impairment
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Nervous system disorders
Normal pressure hydrocephalus
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Nervous system disorders
Paraesthesia
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.68%
2/293 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.51%
3/591 • Number of events 3 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Nervous system disorders
Post herpetic neuralgia
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
2/591 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Nervous system disorders
Sciatica
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.68%
2/293 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.51%
3/591 • Number of events 3 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Nervous system disorders
Syncope
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
1.3%
4/298 • Number of events 4 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.68%
4/591 • Number of events 4 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Nervous system disorders
Vertebral artery stenosis
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Nervous system disorders
Carotid artery occlusion
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Nervous system disorders
Cervical radiculopathy
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.68%
2/293 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
2/591 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Nervous system disorders
Lumbar radiculopathy
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
2/591 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Nervous system disorders
Cognitive disorder
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Nervous system disorders
Peripheral nerve palsy
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Nervous system disorders
Carotid arteriosclerosis
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
2/591 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Psychiatric disorders
Anxiety
|
0.66%
2/301 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.68%
2/293 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
2/591 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Psychiatric disorders
Depression
|
0.66%
2/301 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.68%
2/293 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
1.0%
3/298 • Number of events 3 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.85%
5/591 • Number of events 5 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Psychiatric disorders
Euphoric mood
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Psychiatric disorders
Insomnia
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
2/591 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Psychiatric disorders
Sleep disorder
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Psychiatric disorders
Tension
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Renal and urinary disorders
Dysuria
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Renal and urinary disorders
Haematuria
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
1.0%
3/293 • Number of events 3 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.68%
4/591 • Number of events 4 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Renal and urinary disorders
Nephrolithiasis
|
1.00%
3/301 • Number of events 3 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
1.4%
4/293 • Number of events 4 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.85%
5/591 • Number of events 5 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Renal and urinary disorders
Nephropathy
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Renal and urinary disorders
Nocturia
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Renal and urinary disorders
Proteinuria
|
1.7%
5/301 • Number of events 5 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
1.4%
4/293 • Number of events 4 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.68%
4/591 • Number of events 4 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Renal and urinary disorders
Urinary incontinence
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
2/591 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Renal and urinary disorders
Urinary retention
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Renal and urinary disorders
Urine abnormality
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Renal and urinary disorders
Cystitis noninfective
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Renal and urinary disorders
Chronic kidney disease
|
1.00%
3/301 • Number of events 3 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Renal and urinary disorders
Acute kidney injury
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Renal and urinary disorders
Ureterolithiasis
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Reproductive system and breast disorders
Benign prostatic hyperplasia
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.68%
2/293 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
2/591 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Reproductive system and breast disorders
Gynaecomastia
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Reproductive system and breast disorders
Infertility
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Reproductive system and breast disorders
Ovarian cyst
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Reproductive system and breast disorders
Prostatitis
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Reproductive system and breast disorders
Uterine haemorrhage
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Reproductive system and breast disorders
Prostatomegaly
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.67%
2/298 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
2/591 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Reproductive system and breast disorders
Heavy menstrual bleeding
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Reproductive system and breast disorders
Pelvic organ prolapse
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Respiratory, thoracic and mediastinal disorders
Asthma
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Respiratory, thoracic and mediastinal disorders
Bronchitis chronic
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Respiratory, thoracic and mediastinal disorders
Chronic obstructive pulmonary disease
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Respiratory, thoracic and mediastinal disorders
Cough
|
2.3%
7/301 • Number of events 8 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
2.0%
6/293 • Number of events 6 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
1.0%
3/298 • Number of events 3 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
1.5%
9/591 • Number of events 9 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Respiratory, thoracic and mediastinal disorders
Dyspnoea
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Respiratory, thoracic and mediastinal disorders
Epistaxis
|
0.33%
1/301 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
1.0%
3/293 • Number of events 3 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.68%
4/591 • Number of events 4 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Respiratory, thoracic and mediastinal disorders
Nasal congestion
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Respiratory, thoracic and mediastinal disorders
Rhinitis allergic
|
0.66%
2/301 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Respiratory, thoracic and mediastinal disorders
Rhinorrhoea
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Respiratory, thoracic and mediastinal disorders
Sleep apnoea syndrome
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.68%
2/293 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
2/591 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Respiratory, thoracic and mediastinal disorders
Throat irritation
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Respiratory, thoracic and mediastinal disorders
Pulmonary mass
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Respiratory, thoracic and mediastinal disorders
Paranasal sinus mucosal hypertrophy
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Respiratory, thoracic and mediastinal disorders
Oropharyngeal pain
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
1.4%
4/293 • Number of events 4 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.85%
5/591 • Number of events 5 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Skin and subcutaneous tissue disorders
Acne
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Skin and subcutaneous tissue disorders
Actinic keratosis
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.68%
2/293 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
2/591 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Skin and subcutaneous tissue disorders
Dermatitis
|
1.00%
3/301 • Number of events 3 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Skin and subcutaneous tissue disorders
Dermatitis contact
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Skin and subcutaneous tissue disorders
Dry skin
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Skin and subcutaneous tissue disorders
Eczema
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.67%
2/298 • Number of events 3 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.51%
3/591 • Number of events 4 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Skin and subcutaneous tissue disorders
Eczema asteatotic
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Skin and subcutaneous tissue disorders
Hyperkeratosis
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Skin and subcutaneous tissue disorders
Miliaria
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Skin and subcutaneous tissue disorders
Pruritus
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.68%
2/293 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
2/591 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Skin and subcutaneous tissue disorders
Rash
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
1.0%
3/298 • Number of events 3 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.68%
4/591 • Number of events 4 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Skin and subcutaneous tissue disorders
Skin irritation
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Skin and subcutaneous tissue disorders
Skin ulcer
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Skin and subcutaneous tissue disorders
Stasis dermatitis
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.67%
2/298 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
2/591 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Skin and subcutaneous tissue disorders
Urticaria
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.67%
2/298 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
2/591 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Skin and subcutaneous tissue disorders
Skin swelling
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Skin and subcutaneous tissue disorders
Cutaneous symptom
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Social circumstances
Menopause
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Surgical and medical procedures
Spinal fusion surgery
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Surgical and medical procedures
Skin neoplasm excision
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Surgical and medical procedures
Tooth extraction
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.67%
2/298 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
2/591 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Vascular disorders
Aortic aneurysm
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Vascular disorders
Arteriosclerosis
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.68%
2/293 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
2/591 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Vascular disorders
Blood pressure fluctuation
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Vascular disorders
Embolism venous
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Vascular disorders
Essential hypertension
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Vascular disorders
Hypertension
|
5.0%
15/301 • Number of events 17 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
10.6%
31/293 • Number of events 35 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
8.4%
25/298 • Number of events 28 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
9.5%
56/591 • Number of events 63 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Vascular disorders
Hypotension
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Vascular disorders
Peripheral vascular disorder
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Vascular disorders
Thrombophlebitis
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Vascular disorders
Vein disorder
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Vascular disorders
Deep vein thrombosis
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Vascular disorders
Vascular shunt
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
2/591 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Vascular disorders
Aortic dilatation
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Vascular disorders
Peripheral arterial occlusive disease
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Vascular disorders
Aortic arteriosclerosis
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
2/591 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Vascular disorders
Brachiocephalic arteriosclerosis
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Vascular disorders
Vein rupture
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Vascular disorders
Scalp haematoma
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Blood and lymphatic system disorders
Eosinophilia
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Blood and lymphatic system disorders
Platelet disorder
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Blood and lymphatic system disorders
Thrombocytosis
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Blood and lymphatic system disorders
Retroperitoneal lymphadenopathy
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Cardiac disorders
Acute myocardial infarction
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Cardiac disorders
Mitral valve prolapse
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Cardiac disorders
Sinus tachycardia
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Congenital, familial and genetic disorders
Aberrant aortic arch
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Ear and labyrinth disorders
Deafness transitory
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Endocrine disorders
Goitre
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Endocrine disorders
Hypothyroidism
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Amaurosis fugax
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Angle closure glaucoma
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Cataract subcapsular
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Corneal erosion
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Corneal oedema
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Ectropion
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Exophthalmos
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Eyelid oedema
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Flat anterior chamber of eye
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Lacrimation increased
|
1.00%
3/301 • Number of events 3 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Lens dislocation
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Photopsia
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Retinal depigmentation
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Vitritis
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Lid margin discharge
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Retinoschisis
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Subretinal fluid
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Vitreomacular interface abnormal
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Ocular rosacea
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Chorioretinal folds
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Superior limbic keratoconjunctivitis
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Glaucomatous optic neuropathy
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Gastrointestinal disorders
Abdominal discomfort
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Gastrointestinal disorders
Dyspepsia
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Gastrointestinal disorders
Flatulence
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Gastrointestinal disorders
Duodenogastric reflux
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Gastrointestinal disorders
Abdominal hernia
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Gastrointestinal disorders
Burning mouth syndrome
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Gastrointestinal disorders
Noninfective gingivitis
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Gastrointestinal disorders
Pulpless tooth
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
General disorders and administration site conditions
Catheter site pain
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
General disorders and administration site conditions
Ill-defined disorder
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Hepatobiliary disorders
Cholecystitis
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Immune system disorders
Contrast media reaction
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Immune system disorders
Iodine allergy
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
2/591 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Immune system disorders
Contrast media allergy
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Infections and infestations
Adenoviral conjunctivitis
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Infections and infestations
Bacterial vaginosis
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Infections and infestations
Cellulitis
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Infections and infestations
Ear infection
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Infections and infestations
Folliculitis
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Infections and infestations
Herpes virus infection
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Infections and infestations
Impetigo
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Infections and infestations
Onychomycosis
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Infections and infestations
Otitis media
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Infections and infestations
Paronychia
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Infections and infestations
Pharyngitis streptococcal
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Infections and infestations
Oropharyngeal candidiasis
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Infections and infestations
Infected cyst
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Infections and infestations
Arthritis infective
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Infections and infestations
Borrelia infection
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Infections and infestations
Colonic abscess
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Infections and infestations
Candida infection
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Infections and infestations
Infective keratitis
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Infections and infestations
Bacterial urethritis
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Injury, poisoning and procedural complications
Animal bite
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.68%
2/293 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
2/591 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Injury, poisoning and procedural complications
Head injury
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Injury, poisoning and procedural complications
Humerus fracture
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Injury, poisoning and procedural complications
Injury
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Injury, poisoning and procedural complications
Joint dislocation
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Injury, poisoning and procedural complications
Ligament sprain
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.67%
2/298 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
2/591 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Injury, poisoning and procedural complications
Overdose
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Injury, poisoning and procedural complications
Radius fracture
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Injury, poisoning and procedural complications
Rib fracture
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Injury, poisoning and procedural complications
Fractured coccyx
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Injury, poisoning and procedural complications
Mouth injury
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Injury, poisoning and procedural complications
Abdominal injury
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Injury, poisoning and procedural complications
Eye injury
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Injury, poisoning and procedural complications
Tooth fracture
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Injury, poisoning and procedural complications
Skin abrasion
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Injury, poisoning and procedural complications
Periorbital haemorrhage
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Investigations
Creatine urine increased
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Investigations
Electrocardiogram ST segment depression
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Investigations
Glucose urine present
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Investigations
Heart rate increased
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Investigations
Red blood cell count increased
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 2 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Investigations
Red blood cells urine positive
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Investigations
Reticulocyte count increased
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Investigations
Electrocardiogram T wave abnormal
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Investigations
Nitrite urine present
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Investigations
Urine transitional cells present
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Investigations
Fungal test positive
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Investigations
Blood alkaline phosphatase abnormal
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Investigations
Hepatic enzyme increased
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Investigations
Interferon gamma release assay positive
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Metabolism and nutrition disorders
Hyperglycaemia
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Metabolism and nutrition disorders
Hypovolaemia
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Musculoskeletal and connective tissue disorders
Gouty tophus
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Musculoskeletal and connective tissue disorders
Groin pain
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Musculoskeletal and connective tissue disorders
Neck pain
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Musculoskeletal and connective tissue disorders
Sacroiliitis
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Musculoskeletal and connective tissue disorders
Myofascitis
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Musculoskeletal and connective tissue disorders
Intervertebral disc disorder
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Musculoskeletal and connective tissue disorders
Muscle contracture
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Musculoskeletal and connective tissue disorders
Spinal pain
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Musculoskeletal and connective tissue disorders
Temporomandibular pain and dysfunction syndrome
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Melanocytic naevus
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Squamous cell carcinoma
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Gastrointestinal submucosal tumour
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Nervous system disorders
Carpal tunnel syndrome
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Nervous system disorders
Hydrocephalus
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Nervous system disorders
Hypotonia
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Nervous system disorders
Neuropathy peripheral
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Nervous system disorders
Seizure
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Nervous system disorders
Intercostal neuralgia
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Nervous system disorders
Vascular dementia
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Nervous system disorders
Carotid artery disease
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Nervous system disorders
Occipital neuralgia
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Nervous system disorders
Neurosarcoidosis
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Renal and urinary disorders
Bladder pain
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Renal and urinary disorders
Calculus urethral
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Renal and urinary disorders
Cystitis interstitial
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Renal and urinary disorders
Glomerulonephritis chronic
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Renal and urinary disorders
Glycosuria
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Renal and urinary disorders
Nephrotic syndrome
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Renal and urinary disorders
Renal cyst
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Renal and urinary disorders
Urethral caruncle
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Renal and urinary disorders
Hypertensive nephropathy
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Reproductive system and breast disorders
Dysmenorrhoea
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Reproductive system and breast disorders
Vaginal prolapse
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Reproductive system and breast disorders
Vulval eczema
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Reproductive system and breast disorders
Genitourinary syndrome of menopause
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Respiratory, thoracic and mediastinal disorders
Hypoxia
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Respiratory, thoracic and mediastinal disorders
Interstitial lung disease
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Respiratory, thoracic and mediastinal disorders
Paranasal sinus hypersecretion
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Skin and subcutaneous tissue disorders
Angioedema
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Skin and subcutaneous tissue disorders
Dermatitis allergic
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Skin and subcutaneous tissue disorders
Photosensitivity reaction
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Skin and subcutaneous tissue disorders
Rash macular
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Skin and subcutaneous tissue disorders
Diabetic foot
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Surgical and medical procedures
Hernia repair
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Vascular disorders
Aneurysm
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Vascular disorders
Aortic stenosis
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Vascular disorders
Flushing
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Vascular disorders
Hypertensive crisis
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Vascular disorders
Vasodilatation
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Vascular disorders
Haemorrhage
|
0.00%
0/301 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Vascular disorders
Ischaemia
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Vascular disorders
Vein collapse
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place